Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling.

Molecular cancer therapeutics - 1 Feb 2016

Li Jiannong, Fang Bin, Kinose Fumi, Bai Yun, Kim Jae-Young, Chen Yian A, Rix Uwe, Koomen John M, Haura Eric B

Abstract excerpt

To overcome hurdles in identifying key kinases in small cell lung cancer (SCLC), we integrated a target-agnostic phenotypic screen of kinase inhibitors with target identification using activity-based protein profiling (ABPP) in which a desthiobiotin-ATP probe was used. We screened 21 SCLC cell lines with known c-MYC amplification status for alterations in viability using a chemical library of 235 small-molecule...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biotin
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to Gene Amplification

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-myc

Share to Small Cell Lung Carcinoma

Share to Small Molecule Libraries

Source

Open in PubMed Open full text

Identifiers

PMID: 26772203
DOI: 10.1158/1535-7163.MCT-15-0444
PMCID: PMC4747823

Genes

MYC
TANK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling.PMID 26772203Read ↗

A framework for identification of actionable cancer genome dependencies in small cell lung cancerSemantic proximity Read ↗

Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA ExpressionSemantic proximity Read ↗

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.Semantic proximity Read ↗

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.Semantic proximity Read ↗

Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer.Semantic proximity Read ↗

An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735Semantic proximity Read ↗

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.Semantic proximity Read ↗

Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy.Semantic proximity Read ↗

The Clinical Kinase Index: Prioritizing Understudied Kinases as Targets for the Treatment of CancerSemantic proximity Read ↗

Innovating cancer drug discovery with refined phenotypic screens.Semantic proximity Read ↗

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.Semantic proximity Read ↗

BRCA1 orchestrates the response to BI-2536 and its combination with alisertib in MYC-driven small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.